Quick Answer
Jasper Therapeutics, Inc. reported R&D Expense of $63.10 million for fiscal year 2025.
Jasper Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $63.10M | +13.0% |
| 2024 | $55.82M | +7.8% |
| 2023 | $51.78M | +49.6% |
| 2022 | $34.63M | +36.2% |
| 2021 | $25.42M | +60.1% |
| 2020 | $15.88M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.39M | -0.4% | -32.1% |
| June 30, 2025 | $21.20M | +87.6% | +31.2% |
| March 31, 2025 | $16.16M | +56.9% | +11.8% |
| September 30, 2024 | $14.46M | -2.6% | +28.0% |
| June 30, 2024 | $11.30M | -15.0% | +9.7% |
| March 31, 2024 | $10.30M | +5.0% | -30.6% |
| September 30, 2023 | $14.85M | +64.6% | +11.7% |
| June 30, 2023 | $13.30M | +63.5% | +35.6% |
- Jasper Therapeutics, Inc. showed an increase of +13.0% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Jasper Therapeutics, Inc.’s r&d expense has grown by 297.3% (from $15.88 million to $63.10 million).
- The most recent figure is from Jasper Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: